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Atrial fibrillation (AF) is a common and serious condition, 
affecting at least 1.8% of the population, rising to over 
6% in people aged above 65 years. As the population 
ages, prevalence is increasing. People with AF are five 
times more likely to have a stroke and have an increased 
risk of premature death, resulting in enormous personal, 
social and economic cost. Prevention of stroke is the 
main aim of management. Standard treatment involves 
oral anticoagulant (OAC) drugs – usually warfarin but 
there are new drugs available.  AF is under-diagnosed and 
the use of OACs is inadequate.  There is an urgent need 
to improve diagnosis and to encourage better uptake 
and adherence to OACs.
Our key recommendations are:
•	 Detection of AF must be improved; a national 
screening programme should be introduced.
•	 Uptake of OAC must be increased and methods of 
engaging patients in their AF management should be 
improved.
•	 Aspirin should not be used for stroke prevention in 
AF.
•	 In relation to rate and rhythm control for AF, relief 
of symptoms should be the goal of treatment.
HOW CAN WE BEST DETECT AF?
•	 Detection and thromboprophylaxis of AF should be 
a NHS priority for the prevention of disabling 
cardioembolic stroke with all its consequences for 
individuals and for health and social care resources.
•	 Screening for AF in people of 65 or older satisfies 
the UK National Screening Committee criteria for 
a screening programme and such a national screening 
programme should be undertaken in the UK.
•	 The most cost-effective method for the detection 
of AF in primary care is by opportunistic screening 
of people aged 65 years or older by radial pulse 
checking followed as soon as practicable by a 
12-lead ECG for those with an irregular pulse.
•	 Use of a single lead ECG recording at the time of 
symptoms can help in diagnosis but does not replace 
the need for a 12-lead ECG.
•	 Diagnostic ECGs should be analysed by a competent 
individual supported by audit and feedback.
•	 Where clinical  suspicion  of  paroxysmal AF exists, 
including after ischaemic stroke or transient 
ischaemic attack (TIA), longer ECG monitoring 
periods (at least 24 hours) or event recorders 
should be used.
SHOULD THE TREATMENT OF AF BE 
TARGETED TOWARDS CONTROL OF RHYTHM, 
RATE OR BOTH?
•	 In relation to rate and rhythm control for AF, relief 
of symptoms should be the goal of treatment. The 
risks and benefits of individual treatments should be 
considered and discussed with the patient.
•	 Drug therapy with a beta-blocker remains the 
standard first-line treatment for relief of symptoms. 
For patients with persistent AF, treatment should 
aim to achieve a resting heart rate of <100 beats 
per minute. Patients who remain symptomatic 
should be referred to a specialist for consideration 
of other antiarrhythmic strategies.
•	 Elective electrical cardioversion is useful in selected 
patients but the recurrence rate of AF is high. OAC 
should be continued post-cardioversion dependent 
upon calculated stroke risk.
•	 Procedures, such as left atrial catheter ablation, 
should be considered in patients who remain 
symptomatic despite anti-arrhythmic drug treatment.
•	 Currently there is not enough evidence that ablation 
improves prognosis (e.g. reduces stroke or 
mortality) to recommend it as first-line treatment, 
or in asymptomatic patients. There is a need for 
further evidence in this area.
•	 There is evidence that ablation has a higher success 
rate in maintaining normal heart rhythm in patients 
who are younger or who have paroxysmal AF.
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•	 AF may recur after ablation; OAC should be 
continued post-ablation dependent upon the 
calculated stroke risk.
WHAT IS THE MOST EFFECTIVE AND SAFEST 
DELIVERY OF THROMBOPROPHYLAXIS IN AF?
•	 All patients with AF should have a formal stroke risk 
assessment using a scoring tool such as CHA2DS2- VASc.
•	 Low risk patients (CHA2DS2-VASc=0) should not 
receive long-term thromboprophylaxis.
•	 Patients with paroxysmal, persistent or permanent 
AF who are over the age of 65 or who have any risk 
factor for stroke should be considered for OAC.
•	 Women under 65 years with AF and no other 
stroke risk factors have a relatively low stroke risk 
and thromboprophylaxis would not usually be 
recommended for this group.
•	 Aspirin should not be used for stroke prevention in 
AF as it is ineffective; patients who are taking aspirin 
solely for this purpose should be reviewed.
•	 The combination of aspirin plus clopidogrel reduces 
ischaemic stroke risk in AF but this is offset by a risk 
of serious bleeding. Therefore this combination is 
not recommended for thromboprophylaxis in AF.
•	 Before starting an OAC it is important to assess the 
risks and benefits of treatment, including an 
assessment of cognition and comorbidities.  Use of 
the HAS-BLED tool can help identify modifiable 
bleeding risks which need to be addressed but 
should not on its own be used to exclude patients 
from OAC therapy.
•	 Anticoagulation should be with either well-
controlled warfarin (currently standard treatment) 
or one of the new OACs.
•	 Newer OACs (direct thrombin and factor Xa 
inhibitors) are an option for patients who cannot 
tolerate, have an allergy to, or who cannot achieve 
satisfactory anticoagulant control on warfarin.
•	 All patients with AF should have the risks and 
benefits of OAC assessed annually.
•	 All providers of anticoagulation services should 
provide annual data of TTR (time in therapeutic 
range) as a means of quality improvement.
•	 Anticoagulant control may be improved by near 
patient testing and engaging patients in their own 
care; patient education should be supported at 
every stage.
•	 High risk patients in whom all OACs are 
contraindicated may be considered for a left atrial 
appendage occlusion device.
WHAT ARE THE DIFFERENCES BETWEEN 
PHYSICIAN AND PATIENT EXPECTATIONS 
WITH REGARD TO THE MANAGEMENT OF AF?
•	 Doctors under-prescribe OAC often assuming 
patients are not willing or able to take these drugs 
safely.  This should be addressed.
•	 Patients presenting with AF should have their beliefs 
and expectations about the condition and treatments 
fully explored.
•	 Patients should be allowed time to consider the 
treatment options, having been given appropriate 
written and verbal information, before a decision to 
treat or not is made.
•	 If a patient declines a recommended treatment, 
consideration should be given to revisit the decision 
in the future.
•	 Patients and carers should be provided with 
appropriate information and education and involved 
in shared decision making.
•	 More research with healthcare professionals and 
patients is required to better understand and 
overcome the barriers to optimal use of OAC.
•	 We recommend the development of decision 
support aids involving professionals, patients and 
patient organisations. This should facilitate the 
discussion of the risks and benefits of OACs with 
patients and their families/carers.
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